Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.
What is Jeffrey A. Meckler's net worth?
The estimated net worth of Jeffrey A. Meckler is at least $121,681.90 as of November 18th, 2022. Mr. Meckler owns 65,774 shares of Indaptus Therapeutics stock worth more than $121,682 as of April 1st. This net worth evaluation does not reflect any other assets that Mr. Meckler may own. Learn More about Jeffrey A. Meckler's net worth.
How do I contact Jeffrey A. Meckler?
Has Jeffrey A. Meckler been buying or selling shares of Indaptus Therapeutics?
Jeffrey A. Meckler has not been actively trading shares of Indaptus Therapeutics during the last ninety days. Most recently, on Monday, November 21st, Jeffrey A. Meckler bought 9,600 shares of Indaptus Therapeutics stock. The stock was acquired at an average cost of $1.90 per share, with a total value of $18,240.00. Following the completion of the transaction, the chief executive officer now directly owns 75,374 shares of the company's stock, valued at $143,210.60. Learn More on Jeffrey A. Meckler's trading history.
Who are Indaptus Therapeutics' active insiders?
Are insiders buying or selling shares of Indaptus Therapeutics?
In the last year, Indaptus Therapeutics insiders bought shares 7 times. They purchased a total of 41,185 shares worth more than $101,931.41. The most recent insider tranaction occured on December, 1st when insider Boyan Vesselinov Litchev bought 500 shares worth more than $935.00. Insiders at Indaptus Therapeutics own 36.0% of the company.
Learn More about insider trades at Indaptus Therapeutics. Information on this page was last updated on 12/1/2022.
